Knoxville, Tenn. – (August 31, 2015) – EDP Biotech Corporation, (EDP), a global in vitro diagnostic innovator of simple, blood-based cancer diagnostic tests, announces the publication of key study data for its ColoMarkerÒ ELISA kit. In this clinical research study, ColoMarker demonstrated an overall sensitivity of 97.7% with specificity of 84.4% for all colorectal cancer detection and a nearly 100% sensitivity for early stage (I, II and III) colorectal cancer. Additionally, ColoMarker demonstrated 40% sensitivity to adenomatous polyps. ColoMarker received CE Mark approval as an aid in the detection of early stage colorectal cancer in late 2014.
- US Capital Global Securities Launches $5 Million Equity Investment in Advanced Medical Device Company
- Two more solid announcements from EDP Biotech
- EDP BioTech’s Eric Mayer back from “InnoSTARS” finals in China
- Seeking Alpha: Augury Investments discusses Exact Sciences and EDP Biotech
- One Knoxville company wins, another competing in InnoSTARS China event